Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

- PMLiVE

ALS – innovative developments and investigational treatments

Healthcare experts highlight revolutionary technological developments in ALS care

What do people look for in gene therapy materials? Results from our survey of patients and relatives

By Sam Fraser

Amiculum

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer

Around half of patients who undergo bladder removal surgery experience disease recurrence

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

- PMLiVE

OPEN Health appoints Matt D’Auria as CEO

D’Auria most recently served as CEO of HCG

- PMLiVE

Is critical thinking at risk?

While AI tools offer undeniable benefits, they also risk diminishing our engagement in deep, reflective thinking and learning processes

Group of friends chatting

Content for all – how to connect with neurodiverse audiences

Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.

Cuttsy + Cuttsy

- PMLiVE

OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth

OPEN Health Group is pleased to announce the appointment of Matt D’Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of...

OPEN Health

- PMLiVE

Sanofi’s Qfitlia granted FDA approval to treat haemophilia A or B

Qfitlia is now the first therapy in the US to treat the rare bleeding disorder regardless of inhibitor status

- PMLiVE

Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

Inflammatory bowel disease is estimated to affect nearly two million people across Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links